Reported 2 days ago
Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech company with a market cap of $3 billion, is developing promising therapies for difficult ailments using its proprietary AI platform, Recursion OS. While currently facing financial losses and a low stock price, analysts expect significant growth in revenue, making it a compelling long-term investment despite inherent risks.
Source: YAHOO